{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000192","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.019770+00:00","generated_at":"2026-06-07T15:05:08.517058+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Centessa SerpinPC Phase 2a Part 5 results: 96% median ABR reduction","bullets":["Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline of 35.6.","No thromboembolic events or treatment-related sustained D-dimer elevations observed.","Total target joints reduced by 94% (from 53 to 3) by end of Part 5.","Registrational PRESent-2 and PRESent-3 studies for hemophilia B are ongoing.","No SerpinPC-related adverse events reported in Part 5; favorable safety profile."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000192","json":"https://secwatch.observer/filing/0001847903-23-000192.json","markdown":"https://secwatch.observer/filing/0001847903-23-000192.md","text":"https://secwatch.observer/filing/0001847903-23-000192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000192/0001847903-23-000192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000192/cnta-20231210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:05:08.517058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}